Longitudinal Study of Renal Function in Systemic Sclerosis

REFERENCES

1. 1.↵
   1. Denton CP,
   2. Lapadula G,
   3. Mouthon L,
   4. Muller-Ladner U

   . Renal complications and scleroderma renal crisis. Rheumatology 2009;48 Suppl 3:iii32–5.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Steen VD,
   2. Syzd A,
   3. Johnson JP,
   4. Greenberg A,
   5. Medsger TA Jr.

   . Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol 2005;32:649–55.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Shanmugam VK,
   2. Steen VD

   . Renal manifestations in scleroderma: evidence for subclinical renal disease as a marker of vasculopathy. Int J Rheumatol 2010:Article ID 538589.
4. 4.↵
   1. Carpenter J,
   2. Kenward M

   . Missing data in randomised controlled trials – a practical guide. 2007. [Internet. Accessed June 5, 2012.] Available from: www.lshtm.ac.uk/msu/missingdata.
5. 5.↵
   1. Schnitzer M,
   2. Hudson M,
   3. Baron M,
   4. Steele R; and
   5. Canadian Scleroderma Research Group

   . Disability in systemic sclerosis - a longitudinal observational study. J Rheumatol 2011;38:685–92.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. LeRoy EC,
   2. Black C,
   3. Fleischmajer R,
   4. Jablonska S,
   5. Krieg T,
   6. Medsger TA Jr.,
   7. et al.

   Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202–5.

   OpenUrlPubMed
7. 7.↵
   1. Kronborg J,
   2. Solbu M,
   3. Njolstad I,
   4. Toft I,
   5. Eriksen BO,
   6. Jenssen T

   . Predictors of change in estimated GFR: a population-based 7-year follow-up from the Tromso study. Nephrol Dial Transplant 2008;23:2818–26.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. D’Angelo WA,
   2. Fries JF,
   3. Masi AT,
   4. Shulman LE

   . Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969;46:428–40.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Clements PJ,
   2. Lachenbruch PA,
   3. Furst DE,
   4. Maxwell M,
   5. Danovitch G,
   6. Paulus HE

   . Abnormalities of renal physiology in systemic sclerosis. A prospective study with 10-year followup. Arthritis Rheum 1994;37:67–74.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Scheja A,
    2. Bartosik I,
    3. Wuttge DM,
    4. Hesselstrand R

    . Renal function is mostly preserved in patients with systemic sclerosis. Scand J Rheumatol 2009;38:295–8.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Livi R,
    2. Guiducci S,
    3. Perfetto F,
    4. Ciuti G,
    5. Grifoni E,
    6. Conforti L,
    7. et al.

    Lack of activation of renal functional reserve predicts the risk of significant renal involvement in systemic sclerosis. Ann Rheum Dis 2011;70:1963–7.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. DeMarco PJ,
    2. Weisman MH,
    3. Seibold JR,
    4. Furst DE,
    5. Wong WK,
    6. Hurwitz EL,
    7. et al.

    Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002;46:2983–9.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Furst DE,
    2. Khanna D,
    3. Mattucci-Cerinic M,
    4. Silman AJ,
    5. Merkel PA,
    6. Foeldvari I

    . Scleroderma — developing measures of response. J Rheumatol 2005;32:2477–80.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Scheja A,
    2. Akesson A,
    3. Geborek P,
    4. Wildt M,
    5. Wollheim CB,
    6. Wollheim FA,
    7. et al.

    Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma). Arthritis Res 2001;3:178–82.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Kingdon EJ,
    2. Knight CJ,
    3. Dustan K,
    4. Irwin AG,
    5. Thomas M,
    6. Powis SH,
    7. et al.

    Calculated glomerular filtration rate is a useful screening tool to identify scleroderma patients with renal impairment. Rheumatology 2003;42:26–33.

    OpenUrlAbstract/FREE Full Text